Biliverdin protects against the deterioration of glucose tolerance in db/db mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0006777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0428 (Electronic) Linking ISSN: 0012186X NLM ISO Abbreviation: Diabetologia Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin Springer Verlag
    • Subject Terms:
      Biliverdine/*therapeutic use ; Diabetes Mellitus, Type 2/*drug therapy ; Glucose Intolerance/*drug therapy; Animals ; Apoptosis/drug effects ; Blood Glucose/drug effects ; Body Weight/drug effects ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/metabolism ; Immunohistochemistry ; In Situ Nick-End Labeling ; In Vitro Techniques ; Islets of Langerhans/drug effects ; Islets of Langerhans/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Oxidative Stress/drug effects ; Reverse Transcriptase Polymerase Chain Reaction
    • Abstract:
      Aims/hypothesis: We have previously shown a negative correlation between serum bilirubin levels and prevalence of type 2 diabetes, suggesting that bilirubin inhibits development of this disease. To confirm this hypothesis, we investigated whether administration of biliverdin, the precursor of bilirubin, protects against the deterioration of glucose tolerance in db/db mice, a rodent model of type 2 diabetes.
      Methods: Biliverdin (20 mg/kg daily) was orally administered to 5-week-old db/db mice for 4 weeks. After 4 weeks of treatment, i.p. glucose tolerance and insulin tolerance tests were performed. Insulin content was evaluated by immunostaining and ELISA. Oxidative stress markers (8-hydroxy-2'-deoxyguansosine and dihydroethidium staining) and expression of NADPH oxidase components Pdx1 and Bax were also evaluated in isolated islets.
      Results: Treatment with biliverdin partially prevented worsening of hyperglycaemia and glucose intolerance in db/db mice. This effect was accompanied by a significant increase in insulin content and Pdx1 expression, and a significant decrease of apoptosis and Bax expression in pancreatic islets from db/db mice. At the same time, levels of oxidative stress markers and NADPH oxidase component production in islets were normalised. Biliverdin had little effect on HOMA of insulin resistance or insulin resistance evaluated by insulin tolerance tests.
      Conclusions/interpretation: Biliverdin may protect against progressive worsening of glucose tolerance in db/db mice, mainly via inhibition of oxidative stress-induced beta cell damage.
    • References:
      JAMA. 2007 Sep 26;298(12):1398-400. (PMID: 17895455)
      J Biol Chem. 2004 Oct 8;279(41):42351-4. (PMID: 15258147)
      Diabetologia. 2002 Jan;45(1):85-96. (PMID: 11845227)
      Diabetologia. 2009 Dec;52(12):2489-98. (PMID: 19809798)
      Clin Chem. 1994 Jan;40(1):18-23. (PMID: 8287538)
      Diabetes. 1999 Apr;48(4):927-32. (PMID: 10102716)
      Diabetes Res Clin Pract. 2010 Apr;88(1):103-10. (PMID: 20083320)
      Biochem Soc Trans. 2008 Oct;36(Pt 5):920-9. (PMID: 18793162)
      Clin Chem. 1995 Oct;41(10):1504-8. (PMID: 7586525)
      Diabetologia. 2003 Oct;46(10):1428-37. (PMID: 13680125)
      Arterioscler Thromb Vasc Biol. 1996 Feb;16(2):250-5. (PMID: 8620339)
      J Am Soc Nephrol. 2003 Aug;14(8 Suppl 3):S227-32. (PMID: 12874436)
      Diabetes. 2005 Sep;54(9):2755-63. (PMID: 16123366)
      Diabetes. 2000 Nov;49(11):1939-45. (PMID: 11078463)
      Antioxid Redox Signal. 2004 Oct;6(5):841-9. (PMID: 15345144)
      Diabetes. 2002 Feb;51(2):522-7. (PMID: 11812764)
      Diabetes. 2004 Feb;53 Suppl 1:S110-8. (PMID: 14749275)
      Diabetes. 2003 Jan;52(1):1-8. (PMID: 12502486)
      Biochem Biophys Res Commun. 2005 Jul 15;332(4):927-33. (PMID: 15922295)
      Tohoku J Exp Med. 2010 Jun;221(2):133-40. (PMID: 20495302)
      Diabetologia. 1996 Mar;39(3):357-63. (PMID: 8721784)
      J Biol Chem. 1997 Nov 21;272(47):29911-8. (PMID: 9368067)
      Am J Med. 2008 Sep;121(9):781-788.e1. (PMID: 18724968)
      Kidney Int. 2010 Nov;78(9):905-19. (PMID: 20686447)
      Nature. 2006 Apr 13;440(7086):944-8. (PMID: 16612386)
      Endocrinology. 2009 Nov;150(11):4855-62. (PMID: 19819955)
      Diabetologia. 1978 Jun;14(6):397-404. (PMID: 352776)
      Science. 1987 Feb 27;235(4792):1043-6. (PMID: 3029864)
      Diabetologia. 1999 Aug;42(8):949-57. (PMID: 10491755)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      Biochem Biophys Res Commun. 2005 Jan 7;326(1):60-5. (PMID: 15567152)
      Diabetes. 2003 Jun;52(6):1457-63. (PMID: 12765957)
    • Accession Number:
      0 (Blood Glucose)
      O9MIA842K9 (Biliverdine)
    • Publication Date:
      Date Created: 20110527 Date Completed: 20111108 Latest Revision: 20211020
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/s00125-011-2197-2
    • Accession Number:
      21614569